4 completed. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Reflex Sympathetic Dystrophy: new trials by email Literature Review of Reflex Sympathetic Dystrophy trials Research Report on Reflex Sympathetic Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I Placebo, Neridronic acid 62.5 mg - Complex Regional Pain Syndrome, Type I | Phase 2 / Phase 3 | Completed | Grünenthal GmbH | 459 | 2015-04-01 | 2018-05-09 |
| Effects of Vaporized Marijuana on Neuropathic Pain Mild dose cannabis, Low dose cannabis, Cannabis - Neuropathic Pain, Reflex Sympathetic Dystrophy | Phase 1 / Phase 2 | Completed | University of California, Davis | 44 | 2009-12-01 | 2018-01-31 |
| Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) PEPT, CBO standard - Complex Regional Pain Syndrome, Type I | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 62 | 2009-01-01 | 2013-07-24 |
| A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Lenalidomide - Complex Regional Pain Syndrome (RSD) | Phase 2 | Completed | Celgene Corporation | 40 | 2003-08-01 | 2008-01-03 |
Complex Regional Pain Syndromes (2) · Marijuana Abuse (1) · Multiple Sclerosis (1) · Neuralgia (1) · Neuralgia, Postherpetic (1) · Pain (1) · Peripheral Nervous System Diseases (1) · Somatoform Disorders (1) · Spinal Cord Injuries (1)
Autonomic Nervous System Diseases (4) · Nervous System Diseases (4) · Neuromuscular Diseases (4) · Peripheral Nervous System Diseases (3) · Complex Regional Pain Syndromes (2) · Mental Disorders (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1)
1,10-phenanthroline-platinum(II)-ethylenediamine (1) · 6-amino-1-hydroxyhexane-1,1-diphosphonate (1) · Lenalidomide (1) · nabiximols (1)
Celgene Corporation (1) · Grünenthal GmbH (1) · Radboud University Medical Center (1) · University of California, Davis (1)
United States (3) · Germany (1) · Netherlands (1) · United Kingdom (1)
Barth L Wilsey, MD (1) · Donald Manning, MD, PhD (1)
PMID 22515496, PMID 25919011, PMID 26628523
2014 (1)